{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-060822","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.862116+00:00","generated_at":"2026-06-25T13:50:10.289538+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BrainStorm Q1 2022 net loss $5.4M, cash $18.4M; progresses NurOwn ALS program","bullets":["Net loss $5.4M ($0.15/sh) improved from $6.7M ($0.19/sh) in Q1 2021.","Cash $18.4M at Mar 31, down from $22.1M at Dec 31, 2021.","R&D spend cut to $2.6M from $4.3M; G&A rose to $2.9M from $2.6M.","Presented Phase 3 NurOwn biomarker data at AAN 2022; genetic analysis at MDA conference.","Appointed Netta Blundheim-Shraga as VP R&D and Antal Pearl-Lendener as Chief Legal Counsel."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-060822","json":"https://secwatch.observer/filing/0001104659-22-060822.json","markdown":"https://secwatch.observer/filing/0001104659-22-060822.md","text":"https://secwatch.observer/filing/0001104659-22-060822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465922060822/0001104659-22-060822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465922060822/tm2215644d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T13:50:10.289538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fe47c0424dce20f47f6390f288d151c7e5cd0fa","claim":"BRAINSTORM CELL THERAPEUTICS INC. reported first quarter ended March 31, 2022 results: net income approximately $5.4 million, EPS $0.15.","evidence_excerpt":"Net loss for the three months ended March 31, 2022, was approximately $5.4 million, as compared to a net loss of approximately $6.7 million for the three months ended March 31, 2021. Net loss per share for the three months ended March 31, 2022, and 2021 was $0.15 and $0.19 respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465922060822/0001104659-22-060822-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2022"},{"label":"Net income","value":"approximately $5.4 million"},{"label":"EPS","value":"$0.15"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}